Currently, there are 75.79M common shares owned by the public and among those 60.98M shares have been available to trade.
The company’s stock has a 5-day price change of 1.12% and 19.86% over the past three months. VRNA shares are trading -13.48% year to date (YTD), with the 12-month market performance down to -21.06% lower. It has a 12-month low price of $11.83 and touched a high of $23.81 over the same period. VRNA has an average intraday trading volume of 569.88K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -1.57%, -1.63%, and -4.69% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Verona Pharma Plc ADR (NASDAQ: VRNA) shares accounts for 61.85% of the company’s 75.79M shares outstanding.
It has a market capitalization of $1.37B and a beta (3y monthly) value of 0.43. The earnings-per-share (ttm) stands at -$0.65. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.39% over the week and 4.92% over the month.
Analysts forecast that Verona Pharma Plc ADR (VRNA) will achieve an EPS of $Varonis Systems, Inc. for the current quarter, $49.49 for the next quarter and $Stocks for Type. The lowest estimate earnings-per-share for the quarter is $Avidity Biosciences, Inc. while analysts give the company a high EPS estimate of $Verrica Pharmaceuticals Inc. Comparatively, EPS for the current quarter was $Verona Pharma plc a year ago. Earnings per share for the fiscal year are expected to increase by 29.23%, and -27.72% over the next financial year.
Looking at the support for the VRNA, a number of firms have released research notes about the stock. Jefferies stated their Buy rating for the stock in a research note on May 22, 2023, with the firm’s price target at $35-$38.
